Objective: Recent trials have evaluated adjuvant chemotherapy in patients with non-small-cell lung cancer (NSCLC). For stage IB to IIIA, a significant improvement of treatment results for platin-based chemotherapy was shown, but only one of the 20 patients treated has a benefit of disease-free and overall 5-year survival. In future the implementation of biomarkers, novel agents and individual selection may contribute to better treatment results in adjuvant therapy. Pre-clinical models are one way to study treatment innovations. Materials and methods: We have developed a lung cancer xenograft model. Fresh tumour material of patients with NSCLC was subcutaneously transplanted to immunodeficient mice shortly after surgical resection. In total, 102 samples have been transplanted from which 25 passagable models could be generated. Of the established xenograft lines, 48% were derived from squamous cell carcinomas and 24% from adenocarcinomas. All but one originated from longterm smokers. Results: It could be shown that the early murine passages (maximum 10) were similar to the original tumour with regard to histology and the expression of the surface proteins as E-cadherin, EpCAM or the cell proliferation marker Ki-67. The growth rate of the established xenografts was a unique feature of the different models and not related to patient characteristics or to the histology type. All xenograft models showed a wide variability in response to both classical chemotherapy and targeted anti-epidermal growth factor receptor agents. Response rates were in good accordance with the results of recent clinical studies. Discussion: In summary, we have developed a panel of patient-derived NSCLC xenografts. These xenograft models could be used for pre-clinical studies to evaluate chemotherapy, novel targeted therapies and expression of potential biomarkers. #
Introduction
Cisplatin-based adjuvant chemotherapy in completely resected non-small-cell lung cancer (NSCLC) is becoming a standard in thoracic surgery. Several clinical studies showed a benefit for selected patients after adjuvant chemotherapy [1, 2] . Five of these trials are well summarised in the LACE meta-analysis [3] . This meta-analysis includes more than 4500 patients and a median follow-up of 5 years; platin-based chemotherapy raised the overall survival at 5 years from 43% to 48% with a survival difference of 4.3% at 3 and 5.3% at 5 years, both statistically significant.
However, on average, of the 20 patients receiving a platinbased chemotherapy, only one patient has a long-term benefit. Of those treated, nine out of 20 patients do not benefit, because they did not need any chemotherapy (potentially detected by prognostic biomarkers), while 10 out of 20 patients treated do not benefit, because chemotherapy could not prevent relapse (potentially improved by predictive biomarkers).
Therefore, intensive searches for biomarkers trying to define genes or proteins with prognostic and therapeutic relevance are currently being pursued. These studies mainly use clinical samples [4] , cell lines [5] or cell-line-derived xenograft models [5] [6] [7] . Cell lines are mainly undifferentiated, have a minor relation to the tissue of origin and show less physiological conditions in their micro-environment. Clinical samples are limited in quantity, are heterogeneous and developed under uncontrolled conditions. Only few groups report on patient-derived xenografts [8, 9, 24] , with two groups reporting from xenografts created, in contrast, from patients with advanced or metastatic NSCLC or dedifferentiated cell lines. We decided to establish an extensive panel of patient-derived xenograft models, derived from NSCLC of primarily diagnosed and resected patients (simulating the adjuvant situation). The principal goal of our investigations was to create a realistic model, which allows unlimited repetitions of experimental chemotherapies under controlled conditions with a focus on the adjuvant situation.
In addition, clinical trials in lung cancer patients with novel therapies targeting the epidermal growth factor receptor (EGFR) have been accompanied by great expectations but have so far demonstrated only limited achievement compared to platin-based chemotherapy [10, 11] . Several different reasons for the insufficient responses of anti-EGFR therapies have been discussed [12] . It is beyond doubt that an adequate stratification of patients to be treated with targeted therapies is mandatory but, unfortunately, is not routinely available at present [13] . A secondary goal was to develop a model to study the responses of anti-EGFR.
Materials and methods

Patients, tissue samples and establishment of xenografts
Written informed consent was obtained from each patient and the study was approved by the local ethical committee. From 102 anatomical lung resections, fresh tumour material was transplanted to immunodeficient non-obese diabetic/ severe combined immunodeficient (NOD/SCID) mice (Taconic, Lille Skensved, Denmark). All tumour samples were put into a medium immediately after surgical resection under sterile conditions and transported without delay to the animal facility.
Surgical tumour samples were cut into pieces of 3-4 mm size and transplanted within 30 min after resection subcutaneously (s.c.) to 3-6 mice; for engraftment, the gender of the mice was chosen according to the donor patient.
Additional tissue samples were immediately snap frozen and stored at À80 8C for further analyses. All animal experiments were performed in accordance with the UKCCCR regulations for the Welfare of animals and of the German Animal Protection Law and approved by the local responsible authorities. Mice were observed daily for tumour growth. From these 102 samples, 25 passagable xenograft models were successfully established ( Table 1 ). The samples originated from 12 female (44%) and 13 male (56%) patients. The histological type was determined according to World Health Organisation (WHO) criteria. The collective consisted of 12 squamous cell carcinomas (SQC) (48%), six adenocarcinomas (ADC) (24%) and four carcinomas with a pleiomorphic phenotype (PLC) (16%). The remaining tumours were diagnosed as large cell or de-differentiated carcinomas, and one tumour was secondarily defined as small-cell lung carcinoma. With one exception (ID 7298), the patients were long-term smokers. Pathological staging was determined according to Mountain [14] . Of the 25 patients, four had received chemo-or radiation-therapy before surgery.
At a size of about 1 cm 3 tumours were removed and passaged 2-4 times in the NOD/SCID mice, then they were transferred to naive NMRI:nu/nu mice (Charles River, Sulzfeld, Germany) for chemosensitivity testing. Tumours were passaged in altogether no more than 10 times. Numerous samples from early passages were stored in the tissue bank (liquid nitrogen) and used for further experiments.
Immunohistochemistry
For immunohistochemistry, frozen tissue sections were sliced with a cryotome (Leica CM1900), fixed with 4% paraformaldehyde solution and blocked with 5% goat serum. The sections were incubated with the primary antibodies Ki67 (Dako), E-cadherin (Cell Signaling) or EpCAM (Alexis) for 1 h at ambient temperature or overnight at 4 8C. The antigenantibody reaction was visualised with the LSAB2 system (Dako).
Chemosensitivity testing
The chemotherapeutic response of the passagable tumours was determined in male NMRI:nu/nu mice. For that purpose, one tumour fragment each was transplanted s.c. to a large number of mice. At palpable tumour size (50-100 mm 3 ), 6-8 mice each were randomised to treatment and control groups, and treatment was initiated. The following drugs and treatment modalities were used: Etoposid (Vepesid, Bristol-Meyers Squibb, Italy) 10 Tumour size was measured in two dimensions twice weekly with a caliper-like instrument. Individual tumour volumes (V) were calculated by the formula V = (length + width 2 )/2 and related to the values at the first day of treatment (relative tumour volume, RTV). The median RTV values of the treated to control (T/C) were used for the evaluation of each treatment. The mean tumour doubling time (TDT) of each xenograft model was calculated by comparing the size between two-and fourfold RTV. Statistical analyses in Fig. 2 were performed with the Mann-Whitney U-test; all statistical analyses were performed with Statistica 5.0. Differences were considered significant when the p-value was <0.05. The body weight of mice was determined every 3-4 days and the change in body weight (BWC) was taken as the parameter for tolerability. 
Results
Engraftment of xenografts
From a total of 102 lung cancer specimens transplanted to the immunodeficient mice, 25 passagable xenograft lines were obtained ( Table 1 ). The successful growth in mice was not dependent on any of the clinico-pathological characteristics mentioned. A comparison of the HE-stained original sample with xenografted tumours after a few passages revealed a comparable histological architecture of the primary NSCLC and the xenograft tumour ( Fig. 1A and B) . The staining with the anti-EpCAM or Ki67 antibodies (Fig. 1C  and D) revealed comparable pictures. In general, the tumours revealed a more homogeneous structure during murine passaging due to the replacement of human accessory cells (fibroblasts, endothelial and immune cells) by murine tissues (data not shown). The growth rate of the established xenografts was a unique feature of the different models and seemed not to be related to patient characteristics or to the tumour type (Table 2) . After two to four passages in mice, the composition of the xenograft tissue did not change any further. At that stage, xenograft transplants were archived in the tumour bank, if required re-transplanted and used for chemosensitivity testing and protein analyses.
Chemosensitivity
In order to further characterise the established xenograft models, extensive therapeutic experiments with cytotoxic drugs, clinical standard drugs for treatment of NSCLC, were performed. Table 3 gives an overview on the results obtained and Fig. 2 presents exemplified growth curves of two models following different treatments. Paclitaxel, Gemcitabine and Carboplatin proved to be the most efficient agents in NSCLC xenografts with four and three each out of 25 xenografts, respectively, responding with tumour shrinkage (T/C values <5%). Etoposid (one out of 25 complete remissions) and Vinorelbin (none out of 11 complete remissions) were less efficient.
It became obvious that some models had a high responsiveness towards the majority of agents tested (e.g., 7343, 7462) while others were intrinsically resistant towards a variety of drugs (e.g., 7064, 7198). In general, each tumour had its individual pattern of response to the agents tested, which was independent of the tumour type (e.g., adeno-or squamous cell carcinoma). Table 3 gives an overview on the responsiveness of the xenograft models to anti-EGFR therapies as well. Of the 25 models tested, 12 showed visible responses to Cetuximab (three out of 25 tumour shrinkages) and six out of 25 to Erlotinib (one out of 25 tumour shrinkages). The response rates were quite different among the tumours tested ranging from no response (about 100% T/C in models 7700 and 7612) to complete remissions (about 0% T/C in models 7462 to both anti-EGFR therapies and 7668 to Cetuximab). The responses to anti-EGFR therapies were not related to the histological type of NSCLC or clinical parameters. Interestingly, there was a clear dose-response effect to Erlotinib between 25 and 75 mg kg À1 while this was not obvious for Cetuximab. One model (7177) was moderately sensitive to Erlotinib (T/C 28%) but resistant to Cetuximab, a phenomenon whose mechanism needs further elucidation. 
Discussion
Lung cancer is one of the most frequent tumour types, which presents with a very poor prognosis. Only minor therapeutic success had been made in the last years [15, 16] . Therefore, an intensive search for better treatment modalities was initiated for all tumour stages. Several clinical trials with adjuvant therapies in completely resected NSCLC have been performed, showing a statistically significant improvement of overall and disease-free survival for some patients. However, in general, the number of patients, who benefit from adjuvant chemotherapy, is not high. As a result, these studies revealed an urgent need for a better stratification of patients. So far, no biomarker for prediction of response or outcome of adjuvant chemotherapy has been installed for routine use in NSCLC [17] . One of the possible reasons is that clinical samples used for the analysis of biomarkers were mainly pre-treatment samples and only available in minute amounts, resulting in insufficient material for an extended and repeated study on the protein level. Further, clinical samples are relatively heterogeneous, that is, they contain a variable percentage of cancer cells and other infiltrating cells.
In vivo models used so far for therapeutic studies were derived mainly from established cancer cell lines [18] . These cell lines have been cultivated for a long time in monolayers on plastic dishes and have lost most of their original tumour tissue specificity. In order to circumvent these issues, we used a large panel of xenograft models which were established directly from patient-derived tumour specimens in immunodeficient mice. Our studies [19] and those by others [20] have previously shown that colon cancer xenografts in early passages are very similar to the primary colon cancer from which they were derived with regard to histology, karyotype and chemoresponsiveness.
So far, only few studies used patient-derived lung xenograft models [8, 9, 21, 24] . The study of Judde et al. [21] investigated the response of five xenograft models to Gefitinib in combination with Cisplatin-based chemotherapeutic protocols. We were able to establish 25 routinely passagable NSCLC xenograft models starting from 102 NSCLC specimens. The engraftment rates of NSCLC are lower than the ones observed in our group for colon cancer xenografts with 43% [19] or acute lymphatic leukaemias with 64% [22] but higher than for breast carcinomas with 9% [23] .
In most studies, tumour tissue from patients in advanced stages or highly de-differentiated cell lines have been used. In contrast, we intended to study a cohort of patients undergoing adjuvant chemotherapy.
The NSCLC xenografts showed a high concordance with the corresponding clinical sample both concerning histology and immunohistological staining for Ki67 and EpCAM. Similar results of high comparativeness of xenografts with the original tumour were described by us [19] and others [8] .
The chemoresponsiveness of our panel of NSCLC xenografts revealed a relative sensitivity for Paclitaxel, Gemcitabine and Carboplatin, drugs which also give the highest response rates in the clinical situation. Most of our NSCLC donors were not chemotherapeutically pre-treated; therefore an individual comparison of clinical and xenograft outcome for the donors could not be performed. However, the differential responses of the 25 established xenografts to the single-drug treatments (Table 3) are in good accordance with clinical studies; this fact would highly justify an individual prediction of responsiveness. So far, no validated biomarkers have been developed for routine use, a primary goal for future studies.
In summary, we have developed a large panel of wellcharacterised patient-derived NSCLC xenografts in concordance with the clinical situation. These xenograft models allow to perform pre-clinical studies evaluating novel targeted therapies and uncovering the expression and regulation of biomarkers. Further investigations comparing the therapeutic response of NSCLC xenografts to the expression of resistance markers and growth factor ligands are ongoing.
